Reply letter to the editor concerning the article 'Safety of Sars-Cov-2 vaccines administration for adult patients with hereditary fructose intolerance'
According to the current European medicines legislation, on the labeling is mandatory a warning contraindicating for hereditary fructose intolerance (HFI) patients medicines with oral or parenteral fructose and sorbitol, and oral sucrose, invert sugar, isomaltitol, lactitol and maltitol, but parenteral sucrose is not mentioned. Intravenous administration of sucrose does not increase blood glucose concentrations, because sucrose is poorly oxidized to CO2 and mainly excreted in the urine as a disaccharide; absence of enzimatic activity outside the gut explains why there is not a warning for parenteral sucrose presentations. For this reason, parenteral drugs with sucrose are allowed in HFI patients. Nevertheless, due to interindividual variability and the fact that not all parenterally administered sucrose is recovered in urine, HFI patients need to be closely monitored after parenteral administration of sucrose-containing drugs, especially when the amount exceeds the maximum permissible thresholds.
| Errataetall: |
CommentOn: Hum Vaccin Immunother. 2021 Nov 2;17(11):4112-4114. - PMID 34197272 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Human vaccines & immunotherapeutics - 18(2022), 5 vom: 30. Nov., Seite 2051414 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Izquierdo-Garcia, Elsa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 17.06.2022 Date Revised 03.10.2022 published: Print-Electronic CommentOn: Hum Vaccin Immunother. 2021 Nov 2;17(11):4112-4114. - PMID 34197272 Citation Status MEDLINE |
|---|
| doi: |
10.1080/21645515.2022.2051414 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33888016X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33888016X | ||
| 003 | DE-627 | ||
| 005 | 20231226204434.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/21645515.2022.2051414 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1129.xml |
| 035 | |a (DE-627)NLM33888016X | ||
| 035 | |a (NLM)35358012 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Izquierdo-Garcia, Elsa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Reply letter to the editor concerning the article 'Safety of Sars-Cov-2 vaccines administration for adult patients with hereditary fructose intolerance' |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.06.2022 | ||
| 500 | |a Date Revised 03.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Hum Vaccin Immunother. 2021 Nov 2;17(11):4112-4114. - PMID 34197272 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a According to the current European medicines legislation, on the labeling is mandatory a warning contraindicating for hereditary fructose intolerance (HFI) patients medicines with oral or parenteral fructose and sorbitol, and oral sucrose, invert sugar, isomaltitol, lactitol and maltitol, but parenteral sucrose is not mentioned. Intravenous administration of sucrose does not increase blood glucose concentrations, because sucrose is poorly oxidized to CO2 and mainly excreted in the urine as a disaccharide; absence of enzimatic activity outside the gut explains why there is not a warning for parenteral sucrose presentations. For this reason, parenteral drugs with sucrose are allowed in HFI patients. Nevertheless, due to interindividual variability and the fact that not all parenterally administered sucrose is recovered in urine, HFI patients need to be closely monitored after parenteral administration of sucrose-containing drugs, especially when the amount exceeds the maximum permissible thresholds | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Sucrose |2 NLM | |
| 650 | 7 | |a 57-50-1 |2 NLM | |
| 700 | 1 | |a Alvaro Alonso, Elena Alba |e verfasserin |4 aut | |
| 700 | 1 | |a Montero Pastor, Berta |e verfasserin |4 aut | |
| 700 | 1 | |a Such Díaz, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Escobar Rodríguez, Ismael |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Human vaccines & immunotherapeutics |d 2012 |g 18(2022), 5 vom: 30. Nov., Seite 2051414 |w (DE-627)NLM21576823X |x 2164-554X |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2022 |g number:5 |g day:30 |g month:11 |g pages:2051414 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/21645515.2022.2051414 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2022 |e 5 |b 30 |c 11 |h 2051414 | ||